Co-crystal compound of rivaroxaban and malonic acid

US8466280B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Alfons Grunenberg · Wuppertal, DE
• Karsten Fähnrich · Weil am Rhein, DE
• Olaf Queckenberg · Bensberg, DE
• Christiane Reute · Leverkusen, DE
• Birgit Keil · Düsseldorf, DE
• Karen S. Gushurst · Lafayette, US
• Ezra John Still · West Lafayette, US

Key dates

• Filing date: Jun 3, 2009
• Grant date: Jun 18, 2013
• Expiry date: Dec 12, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel cocrystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid, to processes for its preparation, to medicaments comprising this compound and to their use for controlling diseases.